Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 4Phase 1 4

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 187Neoplasm Metastasis 150Neoplasms 141Leukemia, Myeloid, Acute 138Colorectal Neoplasms 131Breast Neoplasms 120Melanoma 95Ovarian Neoplasms 93Prostatic Neoplasms 89Recurrence 85Multiple Myeloma 83Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Myelodysplastic Syndromes 66Lymphoma, Non-Hodgkin 65Triple Negative Breast Neoplasms 57Glioma 57Stomach Neoplasms 54Endometrial Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Carcinoma, Renal Cell 49Brain Neoplasms 48Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 45Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 40Advanced Solid Tumors 40

Interventions

ribociclib 1palbociclib 1lorlatinib 1encorafenib 1binimetinib 1Fulvestrant 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Sensory and Autonomic Neuropathies × 90 days × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT06308263 2026-04-23

Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
12 enrolled

Hereditary Sensory and Autonomic Neuropathies

NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Totus Medicines

Phase 1 Recruiting
241 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06667141 2026-03-23

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Acrivon Therapeutics

Phase 1 Recruiting
100 enrolled

Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡